Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity
Open accessThe DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Abstract
Cellular senescence is a state of stable growth arrest and a desired outcome of tumor suppressive interventions. Treatment with many anti-cancer drugs can cause premature senescence of non-malignant cells. These therapy-induced senescent cells can have pro-tumorigenic and pro-disease functions via activation of an inflammatory secretory phenotype (SASP). Inhibitors of cyclin-dependent kinases 4/6 (CDK4/6i) have recently proven to restrain tumor growth by activating a senescence-like program in cancer cells. However, the physiological consequence of exposing the whole organism to pharmacological CDK4/6i remains poorly characterized. Here, we show that exposure to CDK4/6i induces non-malignant cells to enter a premature state of senescence dependent on p53. We observe in mice and breast cancer patients that the CDK4/6i-induced senescent program activates only a partial SASP enriched in p53 targets but lacking pro-inflammatory and NF-κB-driven components. We find that CDK4/6i-induced senescent cells do not acquire pro-tumorigenic and detrimental properties but retain the ability to promote paracrine senescence and undergo clearance. Our results demonstrate that SASP composition is exquisitely stress-dependent and a predictor for the biological functions of different senescence subsets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in mouse models have demonstrated that TIS promotes cardiac dysfunction, inflammation, bone loss, muscle weakness, renal and hepatic failure, haematopoietic insufficiency, and overall frailty 27,111,202 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [111]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The proportion of senescent cancer cells in mice exposed to the CDK4/6 inhibitor abemaciclib was comparable to that in mice exposed to doxorubicin, but mice exposed abemaciclib suffered less from detrimental effects owing to a reduction in pro- inflammatory SASP factors 111 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [111]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, despite the marked reduction in the inflammatory SASP response, CDK4/6 inhibition triggers antitumour immunity and favours senescent cell removal 111,153 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [111]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CDK4/6 inhibitor- induced senescent non- malignant and malignant cells largely lack pro- inflammatory SASP factors 111,153 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [111]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Unrestrained proliferation is one of the common hallmarks of cancer cells and a major target for anti-cancer interventions (Hanahan & Weinberg, 2011).”
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690 · cited 1×
“In accordance, pro-inflammatory SASP factors are elevated in cancer patients suffering from a variety of adverse reactions to cancer therapies (Pierce et al , 2009; Ferrucci & Fabbri, 2018).”
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 1×
“…(LY2835219), and ribociclib (LEE011) are approved for the treatment of hormone-sensitive and HER2-negative advanced breast cancer patients, where they have been shown to improve progression-free survival in largely metastasized breast cancer patient cohorts (Finn et al , 2016; Goetz et al , 2017).”
Hallmarks of Cellular Senescence
Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605 · cited 4×
“Drug-treated cells were replated on coverslip in a 24-well plate (3 × 10 4 cells/well) and cultured for 10 or 20 h in the presence of EdU (10 l M), then fixed and stained as previously described (Hernandez-Segura et al , 2018a).”
InfluentialSelf-citationSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“In particular, because cells with PASP only were cleared at a faster rate, it will be interesting to identify PASP factors that facilitate, and NASP factors that interfere with, immune responses (Ventura et al , 2007; Xue et al , 2007; Iannello & Raulet, 2013; Stokes et al , 2019).”
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Four faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070 · cited 1×
“…chemo-and radiotherapy, cause high level of DNA damage in quickly proliferating cells and often achieve tumor suppression by leading cells into senescence — a stable form of growth arrest dependent on the upregulation of cyclin-dependent kinase (CDK) inhibitors p16 and p21 (Rodier & Campisi, 2011).”
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Self-citationRestoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“In particular, because cells with PASP only were cleared at a faster rate, it will be interesting to identify PASP factors that facilitate, and NASP factors that interfere with, immune responses (Ventura et al , 2007; Xue et al , 2007; Iannello & Raulet, 2013; Stokes et al , 2019).”
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744 · cited 1×
“…(LY2835219), and ribociclib (LEE011) are approved for the treatment of hormone-sensitive and HER2-negative advanced breast cancer patients, where they have been shown to improve progression-free survival in largely metastasized breast cancer patient cohorts (Finn et al , 2016; Goetz et al , 2017).”
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · cited 1×
“While non-cancerous cells are likely to have wild-type and functional p53, p53 mutations are observed in > 50% of human malignancies (Muller & Vousden, 2013).”
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · cited 3×
“CDK4/6i-treated cancer cells not only stop dividing but also activate a potent tumor immuno-surveillance (Goel et al , 2017).”
Baar, M. P., Brandt, R. M. C., Putavet, D. A., Klein, J. D. D., Derks, K. W. J., Bourgeois, B. R. M., Stryeck, S., Rijksen, Y., van Willigenburg, H., Feijtel, D. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.031 · Cited by 1,454 · cited 2×
“…senescent (TIS) cells is sufficient to alleviate various therapy-associated adverse reactions including fatigue, myelosuppression, cardiomyopathy, bone loss, frailty, cancer progression, and relapse (Sun et al , 2012; Baar et al , 2017; Demaria et al , 2017; Murali et al , 2018; Yao et al , 2020).”
Inflammatory networks during cellular senescence: causes and consequences.
Freund, A., Orjalo, A. V., Desprez, P.-Y., & Campisi, J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.03.003 · Cited by 1,354 · cited 1×
“Indeed, SASP composition might be dependent on various factors, including tissue, cell type, and time point, and promoted by various signaling pathways, including NF-j B, mTOR, cEBP b , and p38 (Copp (cid:1) e et al , 2010; Freund et al , 2010; Laberge et al , 2015b).”
Cellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338 · cited 5×
“For abemaciclib anti-tumor effect validation, 10 6 fLUC-MMTV-PyMT cancer cells, previously generated (Demaria et al , 2017), were injected into the mammary fat pad of 13-week-old female p16-3MR mice under anesthesia (10 mice).”
InfluentialSelf-citationMitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype
Wiley, C. D., Velarde, M. C., Lecot, P., Liu, S., Sarnoski, E. A., Freund, A., Shirakawa, K., Lim, H. W., Davis, S. S., Ramanathan, A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.11.011 · Cited by 1,275 · cited 1×
“However, recent reports have highlighted those differences in SASP expression might not be only quantitative but also qualitative (Hoare et al , 2016; Wiley et al , 2016).”
Laberge, R.-M., Sun, Y., Orjalo, A. V., Patil, C. K., Freund, A., Zhou, L., Curran, S. C., Davalos, A. R., Wilson-Edell, K. A., Liu, S., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3195 · Cited by 1,160 · cited 1×
“For differential gene expression, we used DESeq2 (Love et al , 2014) to evaluate the genes that were differentially expressed among all the different treatments compared with the vehicle-treated control.”
Self-citationChien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development · doi:10.1101/gad.17276711 · Cited by 1,046 · cited 2×
“Treatment with CDK4/ 6i induces a PASP but not a NF-j B-associated secretory phenotype (NASP), reflecting the high p53 transcriptional activity but the lack of chronic DDR and activation of NF-j B signaling in cells exposed to this treatment (Rodier et al , 2009; Chien et al , 2011).”
Unmasking Transcriptional Heterogeneity in Senescent Cells
Hernandez-Segura, A., de Jong, T. V., Melov, S., Guryev, V., Campisi, J., & Demaria, M. (2017) · Current Biology · doi:10.1016/j.cub.2017.07.033 · Cited by 972 · cited 2×
“However, the SASP is highly heterogeneous and regulated by additional signaling pathways, including cEBPs, NOTCH, mTOR, and SIRT1, suggesting the existence of various modules that are activated in a context-dependent fashion (Hernandez-Segura et al , 2017, 2018b).”
Self-citationCensus and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971 · cited 2×
“Interestingly, among these SASP factors, several were predicted to be p53 target (Fischer, 2017; Fig 4A).”
Induction of the growth inhibitor IGF-binding protein 3 by p53
Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., & Kley, N. (1995) · Nature · doi:10.1038/377646a0 · Cited by 869
The ConsensusPathDB interaction database: 2013 update
Kamburov, A., Stelzl, U., Lehrach, H., & Herwig, R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1055 · Cited by 807
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793 · cited 2×
“…senescent (TIS) cells is sufficient to alleviate various therapy-associated adverse reactions including fatigue, myelosuppression, cardiomyopathy, bone loss, frailty, cancer progression, and relapse (Sun et al , 2012; Baar et al , 2017; Demaria et al , 2017; Murali et al , 2018; Yao et al , 2020).”
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743 · cited 2×
“Moreover, CDK4/6i are currently investigated for treatment of different liquid and solid tumors, including as first-line treatment for lung cancer patients (Patnaik et al , 2016).”
Pierce, B. L., Ballard-Barbash, R., Bernstein, L., Baumgartner, R. N., Neuhouser, M. L., Wener, M. H., Baumgartner, K. B., Gilliland, F. D., Sorensen, B. E., McTiernan, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9068 · Cited by 691 · cited 1×
“In accordance, pro-inflammatory SASP factors are elevated in cancer patients suffering from a variety of adverse reactions to cancer therapies (Pierce et al , 2009; Ferrucci & Fabbri, 2018).”
NOTCH1 mediates a switch between two distinct secretomes during senescence
Hoare, M., Ito, Y., Kang, T.-W., Weekes, M. P., Matheson, N. J., Patten, D. A., Shetty, S., Parry, A. J., Menon, S., Salama, R., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3397 · Cited by 522 · cited 1×
“However, recent reports have highlighted those differences in SASP expression might not be only quantitative but also qualitative (Hoare et al , 2016; Wiley et al , 2016).”
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508 · cited 2×
“Among those, evidences from preclinical and clinical contexts have highlighted the correlation between levels of senescence and severe fatigue (Wang et al , 2020).”
Self-citationCoppé, J.-P., Rodier, F., Patil, C. K., Freund, A., Desprez, P.-Y., & Campisi, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257071 · Cited by 506 · cited 2×
“For example, cells overexpressing p16 or p53 enter a state of senescence without NF-j B signaling and production/secretion of pro-inflammatory and NF-j B-dependent SASP factors (Efeyan et al , 2007; Copp (cid:1) e et al , 2011; Wiley et al , 2018).”
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415 · cited 1×
“In accordance with previous studies (Yang et al , 2017), prolonged treatment of human primary fibroblasts (BJ) with the CDK4/6i abemaciclib was associated with a progressive loss of RB phosphorylation (Fig EV1A ), all features that can also be observed in cells treated with other anti-cancer and…”
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378 · cited 3×
“Systemic administration of CDK4/6i in humans has been reported to be better tolerated than genotoxic interventions (Klein et al , 2018).”
InfluentialCell-Cycle Therapeutics Come of Age
Ingham, M., & Schwartz, G. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0032 · Cited by 353 · cited 1×
“In particular, asthenia (severe fatigue) represents an important obstacle for the continuous treat-ment with genotoxic chemotherapy but is a rare event in patients treated with CDK4/6i (Ingham & Schwartz, 2017).”
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302
van Vliet, T., Varela-Eirin, M., Wang, B., Borghesan, M., Brandenburg, S. M., Franzin, R., Evangelou, K., Seelen, M., Gorgoulis, V., & Demaria, M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.018 · Cited by 172 · cited 4×
“As previously described in Vliet et al (2021), the cut backbone vector was treated with Antarctic phosphatase (cat# M0289S, NEB) before ligation.”
InfluentialSelf-citationThe innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype
Hari, P., Millar, F. R., Tarrats, N., Birch, J., Quintanilla, A., Rink, C. J., Fernández-Duran, I., Muir, M., Finch, A. J., Brunton, V. G., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw0254 · Cited by 154 · cited 1×
“Recent evidences have suggested that, similar to what observed for cancer cells, prolonged treatment with CDK4/6i can promote the premature senescence of non-malignant cells (Guan et al , 2017; Hari et al , 2019).”
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153 · cited 1×
“The anti-cancer effects of CDK4/6i are mainly driven by the induction of cancer cells into senescence (Yoshida et al , 2016; Goel et al , 2017).”
Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0200 · Cited by 140 · cited 1×
“For example, cells overexpressing p16 or p53 enter a state of senescence without NF-j B signaling and production/secretion of pro-inflammatory and NF-j B-dependent SASP factors (Efeyan et al , 2007; Copp (cid:1) e et al , 2011; Wiley et al , 2018).”
Therapy-Induced Senescence Drives Bone Loss
Yao, Z., Murali, B., Ren, Q., Luo, X., Faget, D. V., Cole, T., Ricci, B., Thotala, D., Monahan, J., van Deursen, J. M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2348 · Cited by 129 · cited 2×
“…senescent (TIS) cells is sufficient to alleviate various therapy-associated adverse reactions including fatigue, myelosuppression, cardiomyopathy, bone loss, frailty, cancer progression, and relapse (Sun et al , 2012; Baar et al , 2017; Demaria et al , 2017; Murali et al , 2018; Yao et al , 2020).”
Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
Wiley, C. D., Schaum, N., Alimirah, F., Lopez-Dominguez, J. A., Orjalo, A. V., Scott, G., Desprez, P.-Y., Benz, C., Davalos, A. R., & Campisi, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-20000-4 · Cited by 124 · cited 2×
“For example, cells overexpressing p16 or p53 enter a state of senescence without NF-j B signaling and production/secretion of pro-inflammatory and NF-j B-dependent SASP factors (Efeyan et al , 2007; Copp (cid:1) e et al , 2011; Wiley et al , 2018).”
Sohn, D., Graupner, V., Neise, D., Eßmann, F., Schulze‐Osthoff, K., & Jänicke, R. U. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.17 · Cited by 117 · cited 1×
“Interestingly, RNA-sequencing data suggested that abemaciclib-treated BJ cells differentially expressed several p53 transcriptional targets related to cell cycle (Spurgers et al , 2006; Fischer, 2017; Fig EV1O).”
Spurgers, K. B., Gold, D. L., Coombes, K. R., Bohnenstiehl, N. L., Mullins, B., Meyn, R. E., Logothetis, C. J., & McDonnell, T. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513901200 · Cited by 114 · cited 1×
“Interestingly, RNA-sequencing data suggested that abemaciclib-treated BJ cells differentially expressed several p53 transcriptional targets related to cell cycle (Spurgers et al , 2006; Fischer, 2017; Fig EV1O).”
Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth
Guan, X., LaPak, K. M., Hennessey, R. C., Yu, C. Y., Shakya, R., Zhang, J., & Burd, C. E. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0319 · Cited by 106 · cited 1×
“Recent evidences have suggested that, similar to what observed for cancer cells, prolonged treatment with CDK4/6i can promote the premature senescence of non-malignant cells (Guan et al , 2017; Hari et al , 2019).”
mTORC1 and p53: Clash of the gods?
Hasty, P., Sharp, Z. D., Curiel, T. J., & Campisi, J. (2013) · Cell Cycle · doi:10.4161/cc.22912 · Cited by 94
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Bellutti, F., Tigan, A.-S., Nebenfuehr, S., Dolezal, M., Zojer, M., Grausenburger, R., Hartenberger, S., Kollmann, S., Doma, E., Prchal-Murphy, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0912 · Cited by 76 · cited 1×
“Moreover, it was shown that malignant transformation of hematopoietic cells depends on CDK6-mediated repression of p53 activity and that CDK6 inhibition could reverse this effect (Bellutti et al , 2018).”
Murali, B., Ren, Q., Luo, X., Faget, D. V., Wang, C., Johnson, R. M., Gruosso, T., Flanagan, K. C., Fu, Y., Leahy, K., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0234 · Cited by 67 · cited 2×
“…senescent (TIS) cells is sufficient to alleviate various therapy-associated adverse reactions including fatigue, myelosuppression, cardiomyopathy, bone loss, frailty, cancer progression, and relapse (Sun et al , 2012; Baar et al , 2017; Demaria et al , 2017; Murali et al , 2018; Yao et al , 2020).”
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence
Acevedo, M., Vernier, M., Mignacca, L., Lessard, F., Huot, G., Moiseeva, O., Bourdeau, V., & Ferbeyre, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2347 · Cited by 66 · cited 1×
“Interest-ingly, previous reports have shown that exposure to CDK4/6i leads to epigenetic changes potentially favoring accessibility of p53 to its target genes (Acevedo et al , 2016; Goel et al , 2017).”
Fernández‐Aroca, D. M., Roche, O., Sabater, S., Pascual‐Serra, R., Ortega‐Muelas, M., Sánchez‐Pérez, I., Belandia, B., Ruiz‐Hidalgo, M. J., & Sánchez‐Prieto, R. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.049 · Cited by 63 · cited 1×
“Interest-ingly, previous studies have reported that breast cancer patients carrying p53 mutations are more likely to respond poorly to CDK4/6i (Patnaik et al , 2016), and that breast cancer cells with wild-type p53 are more sensitive to radiotherapy (Fern (cid:1) andez-Aroca et al , 2019).”
Immune Surveillance of Unhealthy Cells by Natural Killer Cells
Iannello, A., & Raulet, D. H. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.020255 · Cited by 54 · cited 1×
“In particular, because cells with PASP only were cleared at a faster rate, it will be interesting to identify PASP factors that facilitate, and NASP factors that interfere with, immune responses (Ventura et al , 2007; Xue et al , 2007; Iannello & Raulet, 2013; Stokes et al , 2019).”
Induction and Validation of Cellular Senescence in Primary Human Cells
Hernandez-Segura, A., Brandenburg, S., & Demaria, M. (2018) · Journal of Visualized Experiments · doi:10.3791/57782 · Cited by 53
Self-citationNatural killer cells limit the clearance of senescent lung adenocarcinoma cells
Stokes, K. L., Cortez-Retamozo, V., Acosta, J., Lauderback, B., Robles-Oteiza, C., Cicchini, M., Pittet, M. J., & Feldser, D. M. (2019) · Oncogenesis · doi:10.1038/s41389-019-0133-3 · Cited by 21 · cited 1×
“In particular, because cells with PASP only were cleared at a faster rate, it will be interesting to identify PASP factors that facilitate, and NASP factors that interfere with, immune responses (Ventura et al , 2007; Xue et al , 2007; Iannello & Raulet, 2013; Stokes et al , 2019).”
Generation of p53 suppressor peptide from the fragment of p53 protein.
Mittelman, J. M., & Gudkov, A. V. (1999) · Somatic Cell and Molecular Genetics · doi:10.1023/a:1018822121890 · Cited by 11 · cited 1×
“BJ cells transduced with a genetic suppressor element (GSE) against p53 (Mittelman & Gudkov, 1999) .”
Research works printed but not linked: 1
- Laberge R‐M, Sun YU, Orjalo AV, Patil CK, Freund A, Zhou L, Curran S, Davalos AR, Wilson‐Edell KA, Liu SU et al (2015b) MTOR regulates the pro‐tumorigenic senescence‐associated secretory phenotype by promoting IL1A translation. Nat Cell Biol 17: 1049– 1061 26147250 PMC4691706 · DOI · Paper page
Cited by
The senescence-associated secretory phenotype and its physiological and pathological implications
Wang, B., Han, J., Elisseeff, J. H., & Demaria, M. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00727-x · Cited by 948
“…factors between TIS fibroblasts (human foreskin fibroblast-derived cell line BJ) and senescent epithelial cells (human retinal pigment epithelial cell line RPE-1) 20 , high through-put analysis showed that less than 50% of SASP proteins were shared between fibroblasts and epithelial cells 137 .”
InfluentialSelf-citationSenescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
Self-citationTargeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs
Kudlova, N., De Sanctis, J. B., & Hajduch, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084168 · Cited by 171
Lai, P., Liu, L., Bancaro, N., Troiani, M., Calì, B., Li, Y., Chen, J., Singh, P. K., Arzola, R. A., Attanasio, G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.005 · Cited by 174
Metadata
- Authors
- Wang, B., Varela‐Eirin, M., Brandenburg, S. M., Hernandez‐Segura, A., van Vliet, T., Jongbloed, E. M., Wilting, S. M., Ohtani, N., Jager, A., & Demaria, M.
- Affiliations
- University Medical Center Groningen (NL)
- Erasmus MC (NL)
- Osaka City University (JP)
- Corresponding author
- Demaria, Marco
- ORCID
- Venue
- The EMBO Journal
- Published
- 2022-01-05
- Volume
- 41
- Issue
- 6
- Pages
- e108946-e108946
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC8922251
- OpenAlex
- W4206812574
- Semantic Scholar
- 18b36d20596ce9b9eae556bc04fab08b715e1596
- Cited by
- 113
- References
- 54
- Citations by year
- 2026: 27 · 2025: 27 · 2024: 29 · 2023: 18 · 2022: 12
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The EMBO Journal (publishedVersion, public-domain)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, public-domain)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- KWF Kankerbestrijding (10989)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cellular senescence, CDK4/6 inhibitors, p53, senescence-associated secretory phenotype, premature senescence, paracrine senescence, NF-κB, breast cancer, drug-induced senescence
- MeSH terms
- Animals, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Tumor Suppressor Protein p53, NF-kappa B, Cellular Senescence, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.